Allergic rhinitis in South Africa: 2012 guidelines.
This report concerns problematic issues in the diagnosis and management of allergic rhinitis (AR) in South Africa, as reviewed by the South African Allergic Rhinitis Working Group (SAARWG) in February 2012.
2. AR in infants
Practical paediatric experience suggests that AR in infants, first reported in 1961, (1) is not uncommon. However, its prevalence is unknown and complicated by inconclusive studies suggesting that 'seasonal AR' is uncommon in the first 2 years of life. (2)
The 2003 prospective study on the influence of perinatal factors on the occurrence of asthma and allergies (PIPO) in Belgium surveyed 1 300 infants from the general population. (3) In the first phase of the study, 260 infants were monitored to the age of 1 year and subjected to a questionnaire, clinical examination and allergy testing. At the end of the first phase, 44% of the infants were reported to have snoring and noisy breathing, while positive allergy test results were reported in 21%. While this does not prove the existence of AR in infancy, it suggests that this diagnosis is probable in some infants.
The following symptoms should be sought where AR is considered in infants: noisy breathing, snuffles, snorting; snoring; sneezing; feeding difficulty; failure to thrive; irritability, disturbed sleep; watery nasal discharge; nose-rubbing on pillow/bedding/mother; recurrent serous otitis media; and cough/wheeze.
Features on examination that suggest AR in infants include: facial appearance (allergic facies); pallor; Dennie-Morgan lines; mouth-breathing; tongue thrusting; a pale, wet and swollen nasal mucosa; serous otitis media; and atopic dermatitis (often present).
Skin-prick tests are useful for identifying allergens, even in very young children, and they require only a limited panel. The most common allergens originate from foods (especially milk, peanut and wheat) and inhalants (especially house dust mite, cats and dogs).
There is no published literature on the manner in which to treat AR in infants. However, 3 aspects of treatment deserve mention:
(i) The avoidance of identified allergens and irritants (especially passive environmental tobacco smoke) is critical. Parents must also be advised to avoid unnecessary and potentially harmful therapies, including most over-the-counter (OTC) cough and cold medications and topical decongestants.
(ii) The use of saline nasal preparations should strongly be recommended.
(iii) All forms of therapy for older children (including antihistamines, topical corticosteroids and montelukast) are not registered for use in infants. While their use is often necessary, clinicians must be careful to balance efficacy with safety.
3. Laboratory-based allergy surveillance in private practice (2007-2011)
Allergy data from South Africa and Africa are limited, with infrequent updates on circulating aero-allergens and the possible impact of climate change. Existing studies are not generalisable, have small sample sizes and assess specific populations. Therefore, alternative ways to audit allergy data have been suggested, including laboratory surveillance of allergy test requests and identified allergens. (4)
To assess the usefulness of laboratory-based allergy surveillance, all allergy test requests and results from 1 September 2007 to 31 August 2011 were extracted from Lancet Laboratories (South Africa and Africa). Test results including total immunoglobulin E (IgE), ImmunoCAP, Immuno solid-phase allergen chip (ISAC), eosinophil cationic protein (ECP) and skin-prick tests were analysed, and data on trends (seasonal), location (country, province and district), doctor type and patient profile (age and sex) were collected.
In total, 1 150 493 allergy-related tests were requested (Table 1), including 129 848 requests for total IgE. Although clinical information was not available, it is assumed that total IgE requests were used primarily as part of an allergy work-up. Most published allergy testing guidelines from South Africa and the rest of the world discourage the use of total IgE as a screening test for allergy. (5,6) The SAARWG stresses the importance of an adequate history in uncovering likely allergens as a source of AR.
The 2011 total paediatric allergy testing expenditure of the large healthcare funder, Discovery Health, approximated R10 million. ImmunoCAP testing contributed to 66% of the expenditure, while 11.2% was spent on total IgE testing in children aged [less than or equal to] 16 years (Discovery Health, 2010). Directed testing according to established algorithms with appropriate screening and follow-up tests must be emphasised in practice.
4. Diagnosis of AR and sinusitis
AR is an inflammatory condition of the lining of the nose, characterised by nasal symptoms, including anterior or posterior rhinorrhoea, sneezing, nasal blockage and/or itching of the nose, often associated with ocular symptoms. (7) Itch, sneeze and profuse rhinorrhoea are classic of early AR. However, nasal obstruction manifests as a prominent symptom with time. (8) Ocular symptoms present with itchy, red and watery eyes. (9)
The diagnosis of sinusitis is guided by a recent European position paper on rhinosinusitis and nasal polyps (EPOS).10 The document makes the case that acute rhinosinusitis is often viral and related to an upper respiratory tract infection (URTI) (Table 2). Acute bacterial sinusitis may be considered when symptoms persist for longer than 10 days. The diagnosis of chronic sinusitis is warranted by symptoms persisting for longer than 12 weeks.
5. AR and sinusitis treatment principles
Intranasal corticosteroids (INS) are the gold-standard first-line therapy for moderate/severe and/or persistent AR. (10) Several studies found INS to be more effective than anti-histamines (AH) against nasal symptoms. (7,11,12) INS treatment may optimise the control of co-morbidities such as asthma, sinusitis, conjunctivitis and otitis media. (13,14)
Acute bacterial sinusitis (ABS) is most often preceded by a viral URTI. Other factors that may lead to inflammation of the nose and paranasal sinuses and predispose to ABS include allergy, trauma and dental infection. Outcomes deemed necessary for managing ABS include eradication of bacterial pathogens from the site of infection, returning the sinuses to health, decreasing the duration of symptoms, preventing severe complications and decreasing the likelihood of chronic disease. There is mounting evidence that topical INS treatment is beneficial in managing ABS. (15,16)
[FIGURE 1 OMITTED]
6. Evidence for the value of OTC cough and cold medicines
OTC cough and cold medicines are frequently used by patients and often prescribed by doctors. Evidence is absent or negative for efficacy for many of these preparations. Cough mixtures have no proven value in adults or children in upper (URT) and lower respiratory tract (LRT) pathologies. (17) Mucolytic agents have been studied and a meta-analysis of 3 studies reveals that they have some benefit in URTIs.18 Oral decongestants and antihistamines have not demonstrated efficacy in most clinical conditions. (19,20)
The lack of efficacy and unfavourable safety profile of many agents is a major concern. The use of most agents in young children has recently been restricted in the USA. (21) However, even legal restriction has not shown changed prescription or usage patterns in many countries. (22)
Topical decongestants improve the major symptoms of nasal congestion in AR. However, their use may produce rhinitis medicamentosa, which may occur as early as day 3 in some patients. Their use should therefore be restricted to no more than 7-10 days. (23)
7. The 'united airway' concept--renewed interest
Despite discussion by world experts on the link between AR and asthma, the SAARWG believes that the evidence strongly supports the concept of a 'united airway' and that the identification and management of both conditions (AR and asthma) improves symptoms and quality of life, reduces severity of disease and is cost-saving. (24-28)
The reasoning for a link between AR and asthma centres on the systemic nature of inflammation in these conditions operating on a common epithelium in both sites. (29)
Patients with persistent AR, affecting quality of life and resistant to maximal therapy, should be assessed for sensitisation. Patients who are monosensitive or 'clinically monosensitive' (i.e. sensitised to more than one allergen but with a clear pattern demonstrating one allergen as the important one) should be offered immunotherapy. (30)
9. Algorithm for the diagnosis and management of rhinitis
An algorithm proposed by the SAARWG for the diagnosis and management of rhinitis in South Africa is presented Fig. 1.
AR is common, important and troubling to patients; therefore, every effort should be made to target therapy correctly. Patient education is important in the management of AR.
SAARWG members: G Carter, G Des Marais, C Els, C Gravett, I Hunt, M Ossip, O F Jooma, A Manjra, L Maron, A Mc Cullogh, M McDonald, P C Potter, R Seedat, and L Woolf.
Endorsements. This Guideline is endorsed by the Allergy Society of South Africa.
Acknowledgements. The SAARWG acknowledges an unrestricted grant from Aspen/GSK Pharmaceuticals for sponsorship of the working group meeting on 10-12 February 2012, where these guidelines were reviewed.
Accepted 11 April 2012.
(1.) Hill LW. Certain aspects of allergy in children. A critical review of the recent literature. N Engl J Med 1961;265:1298-1304. [http://dx.doi.org/ 10.1056/NEJM196112282652607]
(2.) Nickel R, Lau S, Niggemann B, et al. Messages from the German Multicentre Allergy study. Pediatr Allergy Immunol 2002;13 Suppl 15:7-10. [http://dx.doi.org/10.1034/j.1399-3038.13.s.15.4.x]
(3.) Van Bever HP, Desager KN, Hagendorens M. Critical evaluation of prognostic factors in childhood asthma. Pediatr Allergy Immunol 2002;12:1-9. [http://dx.doi.org/ 10.1034/j.1399-3038.2002.00093.x]
(4.) Berman D, Climate change and aeroallergens in South Africa. Curr Allergy Clin Immunol 2011;24:65 71.
(5.) Motala C, Hawarden D. Diagnostic testing in allergy. S Afr Med J 2009;99:531-535. [http://dx.doi.org/ S0256-95742009000700019]
(6.) Eigenmann PA, Oh JW, Beyer K. Diagnostic testing in the evaluation of food allergy. Pediatr Clin North Am 2011;58(2):351-62. [http://dx.doi.org/10.1016/j.pcl.2011.02.003]
(7.) Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-S334.
(8.) Luyt DK, Green RJ, Davis G, et al. Consensus document: allergic rhinitis in South Africa--diagnosis and management. S Afr Med J 1996;56(10):1315-1328.
(9.) Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol Allergy Clin North Am 2005;25(2):263-281.
(10.) Thomas M, Yawn BP, Price D, Lund V, Mullol J, Fokkens W; European Position Paper on Rhinosinusitis and Nasal Polyps Group. EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007--a summary. Prim Care Respir J 2008;17(2):79-89. [http://dx.doi.org/10.3132/pcrj.2008.00029]
(11.) New England Medical Center Evidence-based Practice Center. Management of Allergic and Nonallergic Rhinitis. Evidence Report/Technology Assessment Number 54, 2002.
(12.) Ratner PH, van Bavel JH, Martin BG, et al A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998;47(2):118-125.
(13.) Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-213. [http://dx.doi. org/10.2500/108854199778339053]
(14.) Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57-62.
(15.) Meltzer EO, Teper A, Danzig M. Intranasal corticosteroids in the treatment of acute rhinosinusitis. Curr Allergy Asthma Rep 2008;8(2):133-138. [http://dx.doi.org/10.1007/s11882-008-0023-9]
(16.) Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116(6):12891295. [http://dx.doi.org/10.1016/joaci.2005.08.044]
(17.) Dicpinigatis PV. Currently available antitussives. Pulm Pharm Ther 2009;22:148-151. [http://dx.doi. org/10.1016/j.pupt.2008.08.002]
(18.) Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Collaboration 2010;10. [http:// dx.doi.org/10.1002/14651858.CD006088.pub2]
(19.) Eyibilen A, Alada? I, Guven M, Koc S, Gurbuzler L. The effectiveness of nasal decongestants, oral decongestants and oral decongestant-antihistamines in the treatment of acute otitis media in children. Kulak Burun Bogaz Ihtis Derg 2009;19(6):289-293.
(20.) Shaikh N, Wald ER, Pi M. Decongestants, antihistamines and nasal irrigation for acute sinusitis in children. Cochrane Database of Systematic Reviews 2010;12. [http://dx.doi.org/10.1002/14651858.CD007909.pub2]
(21.) Centers for Disease Control and Prevention (CDC). Revised product labels for pediatric over-the counter cough and cold medicines. MMWR Morb Mort Wkly Rep 2008;57:1180.
(22.) Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, Ceci A, Sturkenboom MC; TEDDY European Network of Excellence. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol 2011;71(6):943-950. [http:// dx.doi.org/10.1111/j.1365-2125.2010.03860.x]
(23.) Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res 2011;3(3):148-156. [http://dx.doi.org/10.4168/aair.2011.3.3.148]
(24.) Huse DM, Harte SC, Russel MW, et al. Allergic rhinitis may worsen asthma symptoms in children: the International Asthma Outcomes Registry. Am J Respir Crit Care Med 1996;153:A860.
(25.) Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma: A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391-1396.
(26.) Welsh PW, Stricker WE, Chu C-P, et al. Efficacy of beclomethasone nasal solution, flunisolide and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987;62:125-134.
(27.) Yawn BP, Yuringer JW, Wollan PC, et al. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health charges. J Allergy Clin Immunol 1999;103:54-59.
(28.) Crystal-Peters J, Neslusan C, Crown WH, et al. Treatment of allergic rhinitis in patients with comorbid asthma: the risk of asthma related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57-62. [http://dx.doi.org/10.1067/mai.2002.120554]
(29.) Corren J. Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 1997;99:S781-S786. [http://dx.doi.org/10.1016/S0091-6749(97)70127-1]
(30.) Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66(6):740-752. [http://dx.doi.org/10.1111/j.1398-9995.2011.02583.x]
Department of Paediatrics and Child Health, University of Pretoria
R J Green, MB BCh, FC Paed (SA), MMed (Paed), PhD, FRCP
Private Practice, Linksfield Clinic, Johannesburg
M Hockman, BSc, MB BCh, FCS (SA) (ORL)
Private Practice, Linksfield Clinic and Sandton Clinic, Johannesburg
R Friedman, MB BCh, FCS (SA) (ORL)
Lancet Laboratories and Division of Medical Virology, Faculty of Health Sciences, Tygerberg Campus, Stellenbosch University
E Vardas, BSc (Hons), MB BCh, DTM&H, DPH, MMed Virology, FC Path Clinical Virology (SA)
Lancet Laboratories, Johannesburg, South Africa
P Cole, MB BCh, MMed (Chem Path)
Private Practice, Netcare Krugersdorp Hospital
A Halkas, MB BCh, FC Paed (SA), MMed (Paed)
Charlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand, Johannesburg
C Feldman, MB BCh, DSc, PhD, FRCP, FCP (SA)
Corresponding author: R J Green (email@example.com)
Table 1. Allergy-related tests conducted by Lancet Laboratories, South Africa and Africa (2007-2011) Number of tests performed (n) 1 September 1 September 1 September 2007-31 2008-31 2009-31 Test August 2008 August 2009 August 2010 IgE 30 199 32 488 33 520 ECP 363 324 314 ImmunoCAP 201 941 244 597 258 104 ISAC N/A N/A 309 Skin-prick test 14 442 15 902 16 255 Total (N) 246 945 293 311 308 502 Number of tests performed (n) Total 1 September (1 September 2010-31 2007-31 Test August 2011 August 2011) IgE 33 641 129 848 ECP 132 1 133 ImmunoCAP 250 109 954 751 ISAC 1 854 2 163 Skin-prick test 15 999 62 598 Total (N) 301 735 1 150 493 N-A = not available; ECP = eosinophil cationic protein; ISAC = Immuno solid-phase allergen chip. Table 2. Diagnosis of acute and chronic sinusitis Chronic rhinosinusitis without Acute bacterial sinusitis (ABS) nasal polyps (CRSsNP) Anterior or post-nasal discharge Anterior or post-nasal discharge OR OR Nasal obstruction Nasal obstruction [+ or -] Facial pain/pressure [+ or -] Facial pain/pressure [+ or -] Change in sense of smell [+ or -] Change in sense of smell ** Lasts >10 days and <3 months * >12 weeks and no nasal polyps ** Severe lasting purulence or temperature ** Worsening in <10 days Chronic rhinosinusitis with Acute bacterial sinusitis (ABS) nasal polyps (CRSwNP) Anterior or post-nasal discharge Anterior or post-nasal discharge OR OR Nasal obstruction Nasal obstruction [+ or -] Facial pain/pressure [+ or -] Facial pain/pressure [+ or -] Change in sense of smell [+ or -] Change in sense of smell ** Lasts >10 days and <3 months * >12 weeks and documented nasal polyps ** Severe lasting purulence or temperature ** Worsening in <10 days * Acute URTI lasting <10 days, no lasting purulence, no worsening, no severe temperature = 'acute viral sinusitis' or 'a cold.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Guidelines; Allergy Society of South Africa|
|Author:||Green, R.J.; Hockman, M.; Friedman, R.; Vardas, E.; Cole, P.; Halkas, A.; Feldman, C.|
|Publication:||South African Medical Journal|
|Date:||Aug 1, 2012|
|Previous Article:||Do South African universities provide the required training platforms for otolaryngology specialist training?|
|Next Article:||South African guidelines for the management of Gaucher disease, 2011.|